Oryzon Genomics S.A./€ORY
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Oryzon Genomics S.A.
Oryzon Genomics S.A. is a Spanish biotechnology company focused on developing innovative therapies through the discovery and development of epigenetic therapeutics. Founded in 2000 and headquartered in Madrid, Spain, Oryzon's research concentrates on LSD1 inhibitors, primarily for oncology and neurodegenerative diseases. The company's leading compounds include iadademstat for cancer treatment and vafidemstat for neurological conditions. Oryzon's unique position in the epigenetics field is supported by its extensive intellectual property portfolio and strategic partnerships with leading pharmaceutical entities. The company operates within the broader pharmaceutical and biotechnology industry, with a specific focus on drug discovery and development.
Ticker
€ORY
Sector
Primary listing
BME
Industry
Biotechnology
Headquarters
Employees
47
Website
ORY Metrics
BasicAdvanced
€219M
-
-€0.06
0.38
-
Price and volume
Market cap
€219M
Beta
0.38
52-week high
€3.69
52-week low
€1.40
Average daily volume
474K
Financial strength
Interest coverage (TTM)
-3.56%
Profitability
EBITDA (TTM)
-4.248
Gross margin (TTM)
95.89%
Net profit margin (TTM)
-57.32%
Operating margin (TTM)
-64.40%
Effective tax rate (TTM)
31.12%
Revenue per employee (TTM)
€144,780
Management effectiveness
Valuation
Price to revenue (TTM)
26.859
Growth
Revenue change (TTM)
-48.05%
Earnings per share change (TTM)
39.74%
3-year revenue growth (CAGR)
-12.30%
10-year revenue growth (CAGR)
-2.99%
3-year earnings per share growth (CAGR)
-8.73%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oryzon Genomics S.A. stock?
Oryzon Genomics S.A. (ORY) has a market cap of €219M as of July 25, 2025.
What is the P/E ratio for Oryzon Genomics S.A. stock?
The price to earnings (P/E) ratio for Oryzon Genomics S.A. (ORY) stock is 0 as of July 25, 2025.
Does Oryzon Genomics S.A. stock pay dividends?
No, Oryzon Genomics S.A. (ORY) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next Oryzon Genomics S.A. dividend payment date?
Oryzon Genomics S.A. (ORY) stock does not pay dividends to its shareholders.
What is the beta indicator for Oryzon Genomics S.A.?
Oryzon Genomics S.A. (ORY) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.